Ligand Pharmaceuticals
LGND
165 hedge funds and large institutions have $1.09B invested in Ligand Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 61 increasing their positions, 38 reducing their positions, and 20 closing their positions.
485% more call options, than puts
Call options by funds: $25.8M | Put options by funds: $4.41M
300% more funds holding in top 10
Funds holding in top 10: 2 → 8 (+6)
165% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 20
61% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 38
53% more capital invested
Capital invested by funds: $712M → $1.09B (+$377M)
25% more funds holding
Funds holding: 132 → 165 (+33)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$51.2M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
+$37.8M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$31M |
| 4 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$30.3M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$27.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.5M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$6.95M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$6.41M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
JP Morgan Chase
New York
| – | -$476K | -17,603 | Closed |
|
|
TMC
177
Trellus Management Company
Delray Beach,
Florida
| – | -$415K | -15,389 | Closed |
|
|
HCM
178
Highbridge Capital Management
New York
| – | -$356K | -13,185 | Closed |
|
179
Westfield Capital Management
Boston,
Massachusetts
| – | -$294K | -10,900 | Closed |
|
180
SG Americas Securities
New York
| – | -$130K | -4,803 | Closed |
|
181
Group One Trading
Chicago,
Illinois
| – | -$142K | -4,351 | Closed |
|
|
ICRM
182
Insight Capital Research & Management
Walnut Creek,
California
| – | -$120K | -3,709 | Closed |
|
183
First Manhattan
New York
| – | -$63K | -2,348 | Closed |
|
|
FA
184
Financial Advantage
Columbia,
Maryland
| – | -$6K | -240 | Closed |
|
|
TRCT
185
Tower Research Capital (TRC)
New York
| – | -$1K | -43 | Closed |
|
LGND Hedge Fund Activity: Q4 2013 in Review
165 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2013, worth a combined $1.09B — up 53% from $712M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new LGND positions and 20 closed out — a net gain of 33 holders — while 61 added to existing stakes and 38 trimmed.
The largest buyer was William Blair & Company, adding an estimated $51.2M. The largest seller was BVF Inc, cutting an estimated $27.6M.
- 165 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2013, up from 132 in Q3 2013.
- Funds reported $1.09B of Ligand Pharmaceuticals stock for Q4 2013, up 53% quarter-over-quarter.
- 53 funds opened new Ligand Pharmaceuticals positions in Q4 2013 and 20 closed out, a net change of +33 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2013 was William Blair & Company, an estimated $51.2M added.
- The largest Ligand Pharmaceuticals seller in Q4 2013 was BVF Inc, an estimated $27.6M sold.
Based on aggregated 13F filings for Q4 2013.